HLA-H: Unlocking The Immune Response (G3136)

Target Name: HLA-H

NCBI ID: G3136

HLA-H

Other Name(s): Major histocompatibility complex, class I, H (pseudogene) | HLAHP | major histocompatibility complex, class I, H (pseudogene)

HLA-H: Unlocking The Immune Response

The Major Histocompatibility Complex (MHC) is a crucial component of the immune system, as it helps to identify and eliminate foreign particles from the body. The HLA-H (MHC class I, H) is a subclass of the MHC that is involved in the presentation of antigens to CD4+ T cells. HLA-H plays a key role in the immune response by presenting antigens to CD4+ T cells, which are then responsible for cell-mediated immunity.

HLA-H is a pseudogene, which means that it was once a functional gene but has lost most of its functional capacity due to evolutionary pressures. Despite its original function, HLA-H has been found to be involved in a number of different processes in the immune system.

One of the functions of HLA-H is to present antigens to CD4+ T cells. This is accomplished through the use of MHC class I molecules, which are complexed with the major histocompatibility complex (MHC) class I molecules. MHC class I molecules are composed of a core protein and a transmembrane protein that are involved in the presentation of antigens to CD4+ T cells.

HLA-H is involved in the presentation of both self-antigens and foreign antigens to CD4+ T cells. Self-antigens are antigens that are present in the body and are recognized by the immune system in order to eliminate them. For example, the HLA-H gene is responsible for the presentation of the major histocompatibility complex (MHC) antigens to CD4+ T cells, which help to recognize and eliminate self-antigens.

In addition to presenting antigens to CD4+ T cells, HLA-H is also involved in the regulation of the immune response. For example, HLA-H has been shown to play a role in the development of autoimmune diseases, in which the immune system attacks the body's own tissues. HLA-H has also been shown to contribute to the regulation of inflammation, as it has been shown to play a role in the production of pro-inflammatory cytokines.

HLA-H has also been found to be involved in a number of different diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune diseases. For example, studies have shown that HLA-H is often expressed in tissues from individuals with multiple sclerosis, a neurodegenerative disease. Additionally, HLA-H has been shown to be involved in the development of cancer, as it has been found to be expressed in a number of tumor types.

Despite its involvement in a number of different processes in the immune system, HLA-H is not well understood. There are currently no FDA-approved drugs that target HLA-H, and research into HLA-H is ongoing. However, studies have shown that HLA-H is a promising biomarker for a number of different diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, HLA-H (MHC class I, H) is a pseudogene that is involved in the presentation of antigens to CD4+ T cells. HLA-H plays a key role in the immune response by presenting antigens to CD4+ T cells, and it is also involved in the regulation of the immune response. Despite its involvement in a number of different processes in the immune system, HLA-H is not well understood and there are currently no FDA-approved drugs that target HLA-H. Further research is needed to fully understand the role of HLA-H in the immune system and its potential as a biomarker for a number of different diseases.

Protein Name: Major Histocompatibility Complex, Class I, H (pseudogene)

Functions: Involved in the presentation of foreign antigens to the immune system

The "HLA-H Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-H comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets